Guggenheim lowered the firm’s price target on Prime Medicine to $20 from $24 and keeps a Buy rating on the shares. The firm’s revised price target accounts for the 22M share dilution after a secondary offering in February as well as higher R&D spending as the CGD clinical program ramps up, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRME:
- Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
- Prime Medicine reports FY23 EPS ($2.18), consensus ($1.97)
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Prime Medicine Announces $150.9M Public Offering and Warrants
